102.30
0.05 (0.05%)
| 前收盘价格 | 102.25 |
| 收盘价格 | 102.25 |
| 成交量 | 1,794,994 |
| 平均成交量 (3个月) | 5,501,872 |
| 市值 | 19,428,497,408 |
| 预期市盈率 (P/E Forward) | 188.68 |
| 价格/销量 (P/S) | 6.03 |
| 股市价格/股市净资产 (P/B) | 8.25 |
| 52周波幅 |
| 营业毛利率 | -36.06% |
| 营业利益率 (TTM) | -11.53% |
| 稀释每股收益 (EPS TTM) | -5.53 |
| 季度收入增长率 (YOY) | 10.90% |
| 总债务/股东权益 (D/E MRQ) | 105.93% |
| 流动比率 (MRQ) | 2.73 |
| 营业现金流 (OCF TTM) | 323.66 M |
| 杠杆自由现金流 (LFCF TTM) | 163.08 M |
| 资产报酬率 (ROA TTM) | -1.83% |
| 股东权益报酬率 (ROE TTM) | -36.89% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Diagnostics & Research (US) | 混合的 | 看涨 |
| Diagnostics & Research (全球的) | 混合的 | 看涨 | |
| 股票 | Exact Sciences Corporation | 看涨 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 1.5 |
| 内部交易活动 | 0.0 |
| 价格波动 | -3.5 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 2.0 |
| 平均 | 0.00 |
|
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening. |
|
| 部门 | Healthcare |
| 行业 | Diagnostics & Research |
| 投资方式 | Small Growth |
| 内部持股比例 | 0.92% |
| 机构持股比例 | 98.89% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 105.00 (Mizuho, 2.64%) | 保留 |
| 105.00 (Evercore ISI Group, 2.64%) | 保留 | |
| 中 | 105.00 (2.64%) | |
| 平均值 | 105.00 (2.64%) | |
| 总计 | 2 保留 | |
| 平均价格@调整类型 | 101.98 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Mizuho | 20 Jan 2026 | 105.00 (2.64%) | 保留 | 102.35 |
| Evercore ISI Group | 05 Jan 2026 | 105.00 (2.64%) | 保留 | 101.61 |
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| CONDELLA SARAH | - | 103.38 | -1,913 | -197,766 |
| CONROY KEVIN T | 103.27 | 103.33 | -25,022 | -2,587,543 |
| 累积净数量 | -26,935 | |||
| 累积净值 ($) | -2,785,309 | |||
| 累积平均购买 ($) | 103.27 | |||
| 累积平均卖出 ($) | 103.34 | |||
| 内部人员交易波幅 ($) | ||||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| CONDELLA SARAH | 职员 | 27 Feb 2026 | 处理 (-) | 1,913 | 103.38 | 197,766 |
| CONDELLA SARAH | 职员 | 27 Feb 2026 | 执行期权 | 3,900 | - | - |
| CONROY KEVIN T | 职员 | 27 Feb 2026 | 处理 (-) | 32,007 | 103.38 | 3,308,884 |
| CONROY KEVIN T | 职员 | 27 Feb 2026 | 执行期权 | 68,097 | - | - |
| CONROY KEVIN T | 职员 | 25 Feb 2026 | 获得 (+) | 13,181 | 103.27 | 1,361,202 |
| CONROY KEVIN T | 职员 | 25 Feb 2026 | 处理 (-) | 6,196 | 103.27 | 639,861 |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合